Quest Diagnostics Inc (DGX) Holdings Lifted by Ardevora Asset Management LLP

Ardevora Asset Management LLP boosted its position in shares of Quest Diagnostics Inc (NYSE:DGX) by 4.8% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 337,168 shares of the medical research company’s stock after buying an additional 15,465 shares during the quarter. Quest Diagnostics accounts for 1.0% of Ardevora Asset Management LLP’s investment portfolio, making the stock its 22nd largest holding. Ardevora Asset Management LLP’s holdings in Quest Diagnostics were worth $36,384,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of DGX. Allianz Asset Management GmbH boosted its stake in Quest Diagnostics by 8.3% during the first quarter. Allianz Asset Management GmbH now owns 2,326,398 shares of the medical research company’s stock worth $233,338,000 after buying an additional 178,041 shares during the period. Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of Quest Diagnostics by 31.4% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 7,532 shares of the medical research company’s stock valued at $754,000 after purchasing an additional 1,800 shares during the period. LPL Financial LLC boosted its stake in shares of Quest Diagnostics by 112.7% during the first quarter. LPL Financial LLC now owns 11,718 shares of the medical research company’s stock valued at $1,175,000 after purchasing an additional 6,208 shares during the period. Principal Financial Group Inc. boosted its stake in shares of Quest Diagnostics by 23.1% during the first quarter. Principal Financial Group Inc. now owns 436,117 shares of the medical research company’s stock valued at $43,743,000 after purchasing an additional 81,936 shares during the period. Finally, Summit Trail Advisors LLC boosted its stake in shares of Quest Diagnostics by 58.5% during the first quarter. Summit Trail Advisors LLC now owns 24,216 shares of the medical research company’s stock valued at $1,769,000 after purchasing an additional 8,936 shares during the period. 86.11% of the stock is owned by institutional investors.

A number of brokerages have recently issued reports on DGX. Argus set a $106.00 target price on shares of Quest Diagnostics and gave the company a “buy” rating in a research note on Wednesday, October 24th. Credit Suisse Group lowered their target price on shares of Quest Diagnostics from $128.00 to $121.00 and set an “outperform” rating for the company in a research note on Wednesday, October 24th. Canaccord Genuity lowered their target price on shares of Quest Diagnostics from $118.00 to $105.00 and set a “buy” rating for the company in a research note on Wednesday, October 24th. Barclays lowered their target price on shares of Quest Diagnostics from $130.00 to $125.00 and set an “overweight” rating for the company in a research note on Wednesday, October 24th. Finally, Citigroup lowered their target price on shares of Quest Diagnostics from $112.00 to $104.00 and set a “neutral” rating for the company in a research note on Wednesday, October 24th. Eight analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $111.13.



NYSE:DGX traded down $0.08 during mid-day trading on Tuesday, reaching $91.75. The company’s stock had a trading volume of 34,448 shares, compared to its average volume of 1,420,673. Quest Diagnostics Inc has a 1 year low of $90.31 and a 1 year high of $116.49. The firm has a market cap of $12.45 billion, a PE ratio of 17.00, a price-to-earnings-growth ratio of 1.65 and a beta of 0.73. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.15 and a quick ratio of 1.09.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings data on Tuesday, October 23rd. The medical research company reported $1.68 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $1.68. Quest Diagnostics had a net margin of 11.30% and a return on equity of 15.71%. The company had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.95 billion. During the same period in the prior year, the firm earned $1.38 earnings per share. The firm’s revenue for the quarter was up 1.8% compared to the same quarter last year. Sell-side analysts anticipate that Quest Diagnostics Inc will post 6.56 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Monday, October 22nd. Investors of record on Friday, October 5th were paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 2.18%. The ex-dividend date of this dividend was Thursday, October 4th. Quest Diagnostics’s dividend payout ratio (DPR) is presently 37.04%.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services.

Recommended Story: Can individual investors take part in an IPO?

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Inc (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply